Ebola Virus Disease: A Comprehensive Guide

Overview

Ebola Virus Disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans caused by the Ebola virus. The virus is part of the Filoviridae family and was first identified in 1976 during outbreaks in Sudan and the Democratic Republic of Congo (near the Ebola River, from which it takes its name).

Who it affects: EVD primarily affects people in regions where the virus is present, particularly in Central and West Africa. However, travelers and healthcare workers exposed to infected individuals can also contract the disease. According to the World Health Organization (WHO), EVD has an average case fatality rate of around 50%, though this varies by outbreak (ranging from 25% to 90%).

Prevalence: Since its discovery, EVD has caused sporadic outbreaks, with the largest occurring in West Africa from 2014 to 2016, resulting in over 28,000 cases and 11,000 deaths (CDC). Smaller outbreaks continue to emerge, such as the 2018-2020 outbreak in the Democratic Republic of Congo, which infected over 3,400 people.

Symptoms

Symptoms of EVD typically appear suddenly between 2 to 21 days after exposure, with an average onset of 8 to 10 days. Early symptoms are often nonspecific and can resemble other illnesses like malaria or influenza. As the disease progresses, symptoms worsen significantly.

Early Symptoms (First Week)

• Fever (often > 38.6°C / 101.5°F): One of the first signs, accompanied by chills.
• Fatigue and weakness: Severe tiredness that interferes with daily activities.
• Muscle and joint pain: Widespread aches, often mistaken for flu.
• Headache: Persistent and often severe.
• Sore throat: May be mild or severe.

Progressive Symptoms (After 5-7 Days)

• Vomiting and diarrhea: Often severe, leading to dehydration.
• Impaired kidney and liver function: May cause jaundice (yellowing of skin/eyes).
• Stomach pain: Can be intense and persistent.
• Unexplained bleeding or bruising: May include bleeding from the eyes, nose, gums, or in vomit/stool (hemorrhagic symptoms occur in about 50% of cases).
• Rash: A maculopapular rash may appear around day 5-7.
• Red eyes (conjunctivitis): Due to inflammation.
• Hiccups: Persistent hiccups can be a late-stage sign.

Note: Not all patients experience hemorrhagic symptoms. Severe cases may progress to shock, seizures, or coma.

Causes and Risk Factors

Causes

EVD is caused by infection with one of the six identified Ebola virus species, four of which are known to cause disease in humans:

• Ebola virus (Zaire ebolavirus): Most common and deadly.
• Sudan virus (Sudan ebolavirus)
• Taï Forest virus (Taï Forest ebolavirus)
• Bundibugyo virus (Bundibugyo ebolavirus)

The virus is introduced into the human population through close contact with bodily fluids (blood, saliva, sweat, urine, feces, vomit, breast milk, or semen) of infected animals, such as:

• Fruit bats (natural hosts)
• Primates (chimpanzees, gorillas, monkeys)
• Forest antelope
• Porcupines

Human-to-human transmission occurs through:

• Direct contact with bodily fluids of infected individuals (alive or deceased).
• Contact with contaminated surfaces, needles, or medical equipment.
• Sexual transmission (virus can persist in semen for months after recovery).

Risk Factors

Certain groups are at higher risk of contracting EVD:

• Healthcare workers: Due to exposure to infected patients.
• Family and friends of infected individuals, especially those caring for them at home.
• Travelers to or residents of areas with active Ebola outbreaks.
• Hunters and butchers who handle bushmeat (wild animal meat).
• Mourners who participate in traditional burial rituals involving direct contact with the deceased.
• Laboratory workers handling Ebola virus samples.

Diagnosis

Diagnosing EVD can be challenging because early symptoms resemble other infectious diseases (e.g., malaria, typhoid fever, or meningitis). However, if EVD is suspected (based on symptoms and exposure history), the following tests may be used:

Diagnostic Tests

• Reverse Transcription-Polymerase Chain Reaction (RT-PCR): Detects Ebola virus genetic material in blood. This is the gold standard for diagnosis.
• Antigen-capture enzyme-linked immunosorbent assay (ELISA): Detects Ebola antigens in blood.
• IgM and IgG antibody tests: Used later in the illness or for surveillance (not for early diagnosis).
• Virus isolation: Growing the virus in cell culture (rarely used due to biosafety risks).

Note: Testing is conducted in high-containment laboratories due to the extreme infectivity of the virus. The CDC recommends testing only for individuals with symptoms and a known exposure risk (e.g., travel to an outbreak area or contact with an infected person).

Treatment Options

There is no specific cure for EVD, but early supportive care significantly improves survival rates. Treatment focuses on managing symptoms and complications while the immune system fights the virus.

Medical Treatments

• Rehydration: Intravenous (IV) fluids or oral rehydration solutions to counteract fluid loss from vomiting and diarrhea.
• Electrolyte replacement: To maintain balance and prevent organ failure.
• Blood pressure support: Medications to maintain circulation.
• Oxygen therapy: For patients with respiratory distress.
• Antiviral medications:
  • Inmazeb (REGN-EB3): A monoclonal antibody cocktail approved by the FDA in 2020 for treating Zaire ebolavirus infection.
  • Ebanga (mAb114): Another monoclonal antibody treatment approved for EVD.
  • Remdesivir: An antiviral initially developed for other viruses, sometimes used under compassionate use protocols.
• Blood transfusions: For patients with severe bleeding.
• Treatment of secondary infections: Antibiotics for bacterial infections.

Experimental Treatments

Several experimental treatments are under investigation, including:

• ZMapp: A monoclonal antibody therapy tested during the 2014-2016 outbreak.
• Favipiravir: An antiviral drug being studied for EVD.

Lifestyle and Home Care

If you are recovering from EVD at home (under medical supervision), follow these guidelines:

• Isolate yourself to prevent spreading the virus.
• Stay hydrated with oral rehydration solutions.
• Rest and avoid physical exertion.
• Monitor symptoms closely and report worsening conditions immediately.
• Avoid sexual activity or use condoms for at least 12 months after recovery (or until testing confirms the virus is no longer present in semen).

Living with Ebola Virus Disease

Survivors of EVD may face long-term health issues, known as Post-Ebola Syndrome. These can include:

• Fatigue and muscle pain
• Joint pain and arthritis
• Eye problems (e.g., uveitis, vision loss)
• Hearing loss
• Neurological issues (e.g., memory loss, headaches)
• Mental health challenges (e.g., depression, anxiety, PTSD)

Daily Management Tips for Survivors

• Regular medical follow-ups: Monitor for complications like eye or joint issues.
• Physical therapy: To regain strength and mobility.
• Mental health support: Counseling or support groups for trauma and stress.
• Eye and hearing checks: Regular evaluations to detect and treat complications early.
• Hydration and nutrition: A balanced diet to support recovery.
• Avoid pregnancy for 6-12 months: Ebola virus can persist in semen and other bodily fluids.

Prevention

Preventing EVD relies on avoiding exposure and controlling outbreaks. Here’s how to reduce your risk:

General Prevention Measures

• Avoid travel to outbreak areas: Check CDC travel advisories before traveling.
• Practice good hygiene:
  • Wash hands frequently with soap and water (or use alcohol-based hand sanitizer).
  • Avoid touching your face (eyes, nose, mouth) with unwashed hands.
• Avoid contact with bodily fluids of infected individuals or animals.
• Do not handle bushmeat or animals found dead in outbreak areas.
• Use protective gear if caring for someone with EVD (gloves, masks, gowns, eye protection).

For Healthcare Workers

• Follow strict infection control protocols (e.g., wearing PPE, proper disposal of medical waste).
• Isolate suspected or confirmed EVD patients immediately.
• Use dedicated medical equipment for EVD patients to prevent cross-contamination.

Vaccination

Two vaccines have been developed to protect against EVD:

• Ervebo (rVSV-ZEBOV): Approved by the FDA and WHO for individuals 18 years and older. It is highly effective (97.5% efficacy) against the Zaire ebolavirus species.
• Ad26.ZEBOV/MVA-BN-Filo: A two-dose vaccine approved by the European Medicines Agency for adults and children over 1 year old.

Vaccination is recommended for:

• Healthcare workers in outbreak areas.
• Laboratory workers handling Ebola samples.
• Contacts of confirmed EVD cases (ring vaccination strategy).

Complications

If left untreated, EVD can lead to life-threatening complications, including:

• Multi-organ failure: Kidney and liver failure are common.
• Septic shock: Dangerously low blood pressure due to infection.
• Severe bleeding (hemorrhage): Internal or external bleeding that can be fatal.
• Neurological damage: Seizures, confusion, or coma.
• Death: Without treatment, fatality rates can exceed 90% in some outbreaks.

Even with treatment, survivors may experience long-term complications, as mentioned in the Living with Ebola Virus Disease section.

When to Seek Emergency Care

Additional Resources

For more information, visit these reputable sources:

• World Health Organization (WHO) - Ebola
• Centers for Disease Control and Prevention (CDC) - Ebola
• Mayo Clinic - Ebola Virus
• National Institutes of Health (NIH) - Ebola Research